The Kevin Rose Show
Beyond Ozempic: The Probiotic That Finally Stops Chocolate (& Food) Binges. Join Our Science Trial. (#72)
Oct 28, 2024
Dr. Colleen Cutcliffe, CEO of Pendulum Therapeutics and an expert in biochemistry, reveals a groundbreaking probiotic that stimulates natural GLP-1 production. She shares why traditional GLP-1 drugs like Ozempic are being challenged by this new approach. Listeners learn about impressive trial results showing reduced food cravings and the complexities of probiotic production. Colleen also discusses the importance of keystone strains in the microbiome and the potential benefits for managing obesity and diabetes.
32:20
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Pendulum Therapeutics' new probiotic formulation enhances natural GLP-1 production, significantly reducing food cravings and promoting healthier eating habits.
- The innovative manufacturing process for anaerobic strains underscores the complex challenges in probiotic development, emphasizing the company's dedication to quality and efficacy.
Deep dives
Microbiome Insights and Opportunities
Probiotics available on the market currently represent less than 1% of the human microbiome, indicating a significant opportunity for innovative interventions. Research has shown that a new formulation can effectively lower A1C levels by 0.6 and blood glucose spikes by 33% in individuals with type 2 diabetes, on par with pharmaceutical outcomes. This microbiome intervention, which leverages previously unexplored strains, demonstrates potential for enhancing metabolic health. The emphasis on the gut metabolism axis aims to empower individuals through restored functions in their microbiome.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
